News – Page 1041 – Endpoints News

Takeda CEO Christophe Weber finally closes on his $62B deal to buy Shire — now he has to convince shareholders and ...

8 years ago

Autolus engineers a $100M-plus IPO for itself as it blueprints a new generation of better, safer cell therapies

8 years ago

Set to be the first pre-revenue biotech to list in Hong Kong, Ascletis lays out priorities in IPO application

8 years ago

Takeda closes in on a final $64B deal to buy Shire, starts to consider divestitures — reports

8 years ago

Allergan aesthetics chief David Moatazedi becomes CEO of Evolus; CARB-X invests $6.2M into Melinta's next-gen ...

8 years ago

Genentech R&D leader Dietmar Berger moves to Atara Bio, heading up off-the-shelf T cell work

8 years ago

Is biopharma’s first $1.5M therapy now in Phase III?

8 years ago

As a prominent analyst predicts (eventual) drug price controls, biopharma braces for a blow while Trump balls his ...

8 years ago

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind ...

8 years ago

With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med ...

8 years ago

Splat: Singapore's Aslan tanks on Nasdaq debut, raising $42M in IPO and trending down

8 years ago

Regeneron ditches higher dose of pain drug fasinumab in PhIII, triggering safety scare; In a small win for Alnylam, ...

8 years ago

C4 Therapeutics bumps Andrew Phillips to CEO; Milind Deshpande exits Achillion; Leena Gandhi to head up I/O at Eli ...

8 years ago

Celgene works to calm down anxious investors, promising to re-file ozanimod at the FDA in early 2019

8 years ago

For shame: ‘Pharma Bro’ Shkreli is in prison, but Daraprim’s price is still high

8 years ago

Sarepta CEO Doug Ingram scored a chart-topping $57M compensation deal in 2017. Earning it won’t be easy

8 years ago

In a comeback, Portola scores FDA accelerated approval for once-rejected Andexxa

8 years ago

Rejected: After paying $80M to acquire it, Mallinckrodt's jaundice drug snubbed by FDA's advisory committee

8 years ago

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

8 years ago

Merck doubles down on Moderna's mRNA cancer vaccines, paying $125M to partner on KRAS shared antigen strategy

8 years ago

After raising VC money weeks ago, Unity tacks on an $85M IPO; Abpro sets terms for $60M IPO

8 years ago

FDA motions Alnylam's lumasiran into a PhIII short track, setting up a shot at an OK in '20

8 years ago

Merck study may signal doom for a broad group of pivotal Alzheimer’s studies

8 years ago

Raising a record $668M in new fund, Foresite sets sights on a tech-driven portfolio

8 years ago

First page Previous page 1038 1039 104010411042 1043 1044 Next page Last page